Markus Warmuth

NetSuite Salesforce Route 53 Mimecast Outlook Microsoft Office 365 Google Cloud Hosting Amazon AWS WP Engine Atlassian Cloud Adobe Marketing Cloud iCIMS Typekit Vimeo Mobile Friendly Google Tag Manager WordPress.org Akamai RUM New Relic Google Analytics Nginx reCAPTCHA IoT Remote AI

biotechnology: biological products (no diagnostic substances) health care biotechnology research molecular glue degraders mgd therapy target protein degradation cancer treatment autoimmune disease inflammatory diseases queen discovery engine proteomics structural biology ai in drug discovery myc-driven tumors oral drug development radiation oncogenesis protein selectivity e3 ligase clinical trials biotechnology drug discovery biopharmaceuticals proteasome pathway ubiquitin-tagging druggable targets biomarker development targeted therapy small molecule drugs drug resistance therapeutic proteins precision medicine pharmaceutical innovation pharmacodynamics phase 1 clinical trials high throughput screening customized drug design translational medicine neurodegenerative diseases immunology cancer biomarkers drug interactions novel cancer targets soluble proteins biological pathways cell signaling therapeutic antibodies chemotherapy alternatives personalized therapeutics cancer immunotherapy pharmacogenomics drug safety profiles protein degradation oncology autoimmune diseases queen platform clinical-stage therapeutics targeted therapies small molecule medicines innovative therapies gspt1 mrt-2359 mrt-6160 mrt-8102 ai-driven drug design strategic partnerships novartis roche healthcare professionals oncologists cancer patients therapeutic pipeline unmet medical needs drug development competitive landscape emerging biotech transformative treatments patient-centric solutions health wellness & fitness hospital & health care